Sono-Tek Q2 profit misses estimates as higher costs outweigh margin gains

By Reuters News


Overview

  • US ultrasonic coating systems maker's Q2 revenue rose 1% yr/yr, gross margin expanded to 53%

  • EPS for Q2 declined to $0.02 from $0.03 in prior-year period

  • Company reiterates flat to modest revenue growth guidance for FY 27, citing timing of large orders


Outlook

  • Sono-Tek reiterates expectation of flat to modest revenue growth for FY 27

  • Company says recent large orders significantly increase revenue visibility for FY 28

  • Sono-Tek sees quarter-to-quarter revenue variability due to timing of large orders


Result Drivers

  • MEDICAL SALES SURGE - Co said medical market sales rose 209% in Q2, led by shipments of balloon coating and specialty stent-coating systems

  • PRODUCT AND GEOGRAPHIC MIX - Co attributed expanded Q2 gross margin to an unusually favorable product and geographic mix

  • HIGHER OPERATING EXPENSES - Co said increased operating expenses partially offset gross profit gains in Q2


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q2 Revenue

Miss

$5.23 mln

$5.54 mln (2 Analysts)

Q2 EPS

Miss

$0.02

$0.04 (2 Analysts)

Q2 Net Income

$366,000


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the industrial machinery & equipment peer group is "buy"

  • Wall Street's median 12-month price target for Sono-Tek Corp is $8.50, about 19.4% above its October 13 closing price of $7.12

  • The stock recently traded at 58 times the next 12-month earnings vs. a P/E of 55 three months ago


Reuters Recommended Reads

  • Oct 12 - Bristol Myers' lung disease drug succeeds at lower dose in late-stage trial

  • Oct 12 - Bristol Myers radiopharma cancer drug slows rare tumor progression in study


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.